EUVIMEDEUVIMED entdecken
Crossref

Impact of voriconazole/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real‐world study

Meng-Meng Jia iD, Dao Wang, Jing Yang

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Meng-Meng Jia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Voriconazole, Triazoles, Hematopoietic Stem Cell Transplantation, Immunosuppressive Agents. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Henan Province Medical Science and Technology Tackling Key Problems Provincial and Ministerial Joint Construction Youth Project, Henan Provincial Science and Technology Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of this study is to investigate the key factors influencing the extent of DDI between cyclosporine A (CsA, GtoPdb Ligand ID: 2162) and voriconazole (VCZ, GtoPdb Ligand ID: 6424)/posaconazole (PCZ, GtoPdb Ligand ID: 6426) in Chinese paediatric allo‐HSCT recipients and to establish evidence‐based dose adjustment strategies.

Methods

One‐hundred‐four children were enrolled and already taking stable doses of oral CsA when voriconazole or posaconazole was initiated. Evaluate the CsA dose and body weight‐adjusted dose‐normalized concentration (C/D) required to achieve therapeutic trough concentration (Cmin) before and after initiation of voriconazole or posaconazole.

Results

CsA C/D increased by 173.37% during VCZ co‐therapy and 132.90% during PCZ co‐therapy. The magnitude of change in CsA C/D was significantly associated with CYP2C19 (GtoPdb Enzyme ID: 1043) genotype and PCZ Cmin. For maintaining therapeutic CsA exposure, the required percentage reduction in CsA dose varied according to CYP3A5 (GtoPdb Enzyme ID: 1040) genotype and age. In the VCZ group, dose reductions ranged from 22.22% to 43.47% across age and CYP3A5 genotype subgroups. In the PCZ group, dose reductions ranged from 12.77% to 33.34% across corresponding subgroups.

Conclusion

CYP2C19 genotype and PCZ Cmin independently affect the magnitude of the DDI between CsA and VCZ/PCZ in paediatric allo‐HSCT patients, and CYP3A5 genotype and age of children should be integrated to guide individualized CsA dose reduction when co‐administered with VCZ or PCZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleTriazolesHematopoietic Stem Cell TransplantationImmunosuppressive AgentsCyclosporineAntifungal AgentsHumansChildFemaleChild, PreschoolCytochrome P-450 CYP2C19MaleAdolescentDrug InteractionsInfantGenotypeDose-Response Relationship, DrugTransplantation, HomologousCytochrome P-450 CYP3A

Stichwörter der Autor:innen

CYP2C19CYP3A5CsApaediatric patientsposaconazolevoriconazole

Substanzen

VoriconazoleTriazolesImmunosuppressive AgentsCyclosporineCytochrome P-450 CYP2C19posaconazoleAntifungal AgentsCYP2C19 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3A

Autor:innen und Institutionen

  • Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Henan Engineering Research Center for Application and Translation of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
  • Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Meng-Meng Jia

Förderung

  • National Key Research and Development Program of China
  • Henan Province Medical Science and Technology Tackling Key Problems Provincial and Ministerial Joint Construction Youth Project
  • Henan Provincial Science and Technology Research Project
  • National Basic Research Program of China

Zitieren

APA

Jia, M. M., Wang, D., & Yang, J. (2026). Impact of voriconazole/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real‐world study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70609

Vancouver

Jia MM, Wang D, Yang J. Impact of voriconazole/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real‐world study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70609

BibTeX
@article{Jia2026,
  author = {Jia, Meng-Meng and Wang, Dao and Yang, Jing},
  title = {Impact of voriconazole/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real‐world study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70609}
}
Kostenlos starten →